TY - JOUR
T1 - Diagnosis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome With Partial Least Squares Discriminant Analysis
T2 - Relevance of Blood Extracellular Vesicles
AU - González-Cebrián, Alba
AU - Almenar-Pérez, Eloy
AU - Xu, Jiabao
AU - Yu, Tong
AU - Huang, Wei E.
AU - Giménez-Orenga, Karen
AU - Hutchinson, Sarah
AU - Lodge, Tiffany
AU - Nathanson, Lubov
AU - Morten, Karl J.
AU - Ferrer, Alberto
AU - Oltra, Elisa
N1 - Publisher Copyright:
Copyright © 2022 González-Cebrián, Almenar-Pérez, Xu, Yu, Huang, Giménez-Orenga, Hutchinson, Lodge, Nathanson, Morten, Ferrer and Oltra.
PY - 2022/4/1
Y1 - 2022/4/1
N2 - Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a chronic disease characterized by long-lasting persistent debilitating widespread fatigue and post-exertional malaise, remains diagnosed by clinical criteria. Our group and others have identified differentially expressed miRNA profiles in the blood of patients. However, their diagnostic power individually or in combinations seems limited. A Partial Least Squares-Discriminant Analysis (PLS-DA) model initially based on 817 variables: two demographic, 34 blood analytic, 136 PBMC miRNAs, 639 Extracellular Vesicle (EV) miRNAs, and six EV features, selected an optimal number of five components, and a subset of 32 regressors showing statistically significant discriminant power. The presence of four EV-features (size and z-values of EVs prepared with or without proteinase K treatment) among the 32 regressors, suggested that blood vesicles carry relevant disease information. To further explore the features of ME/CFS EVs, we subjected them to Raman micro-spectroscopic analysis, identifying carotenoid peaks as ME/CFS fingerprints, possibly due to erythrocyte deficiencies. Although PLS-DA analysis showed limited capacity of Raman fingerprints for diagnosis (AUC = 0.7067), Raman data served to refine the number of PBMC miRNAs from our previous model still ensuring a perfect classification of subjects (AUC=1). Further investigations to evaluate model performance in extended cohorts of patients, to identify the precise ME/CFS EV components detected by Raman and to reveal their functional significance in the disease are warranted.
AB - Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a chronic disease characterized by long-lasting persistent debilitating widespread fatigue and post-exertional malaise, remains diagnosed by clinical criteria. Our group and others have identified differentially expressed miRNA profiles in the blood of patients. However, their diagnostic power individually or in combinations seems limited. A Partial Least Squares-Discriminant Analysis (PLS-DA) model initially based on 817 variables: two demographic, 34 blood analytic, 136 PBMC miRNAs, 639 Extracellular Vesicle (EV) miRNAs, and six EV features, selected an optimal number of five components, and a subset of 32 regressors showing statistically significant discriminant power. The presence of four EV-features (size and z-values of EVs prepared with or without proteinase K treatment) among the 32 regressors, suggested that blood vesicles carry relevant disease information. To further explore the features of ME/CFS EVs, we subjected them to Raman micro-spectroscopic analysis, identifying carotenoid peaks as ME/CFS fingerprints, possibly due to erythrocyte deficiencies. Although PLS-DA analysis showed limited capacity of Raman fingerprints for diagnosis (AUC = 0.7067), Raman data served to refine the number of PBMC miRNAs from our previous model still ensuring a perfect classification of subjects (AUC=1). Further investigations to evaluate model performance in extended cohorts of patients, to identify the precise ME/CFS EV components detected by Raman and to reveal their functional significance in the disease are warranted.
KW - biomarker
KW - carotenoids
KW - extracellular vesicles (EVs)
KW - microRNAs
KW - myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)
KW - partial least squares-differential analysis (PLS-DA)
KW - Raman spectroscopy
UR - https://www.scopus.com/pages/publications/85128514939
UR - https://www.scopus.com/pages/publications/85128514939#tab=citedBy
U2 - 10.3389/fmed.2022.842991
DO - 10.3389/fmed.2022.842991
M3 - Article
AN - SCOPUS:85128514939
SN - 2296-858X
VL - 9
JO - Frontiers in Medicine
JF - Frontiers in Medicine
M1 - 842991
ER -